Evgen Pharma plc announced the resignation with immediate effect of Stephen Franklin as Chief Executive Officer of the Company. Having led Evgen for over 12 years Steve has, with the support of the Board, decided to pursue other opportunities. Barry Clare will become Executive Chairman on a temporary basis until a new CEO is appointed with the appropriate experience to take Evgen through the next exciting stages of its development.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.75 GBX | 0.00% | 0.00% | -53.12% |
Apr. 26 | Evgen Pharma plc will Change its Ticker to TCF from EVG | CI |
Apr. 26 | Evgen Pharma plc will Change its Name to TheraCryf plc | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-53.12% | 4.03M | |
+7.52% | 111B | |
+11.38% | 106B | |
-12.64% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-8.58% | 16.81B | |
+37.41% | 12.54B | |
-23.95% | 8.09B |
- Stock Market
- Equities
- EVG Stock
- News Theracryf Plc
- Evgen Pharma plc Announces Resignation of Stephen Franklin as Chief Executive Officer